New smart chemo targets HER-2 cancers in early trial
Disease control
Recruiting now
This early-phase study tests HF158K1, a chemotherapy drug wrapped in a special coating that targets HER-2, a protein on some cancer cells. The goal is to see if it is safe and can shrink tumors in people with advanced solid tumors that have not responded to other treatments. Abou…
Phase: PHASE1 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC